NHS waiting list falls to lowest level in almost three years

NHS England data show the planned treatment waiting list fell to an estimated 7.31 million treatments (6.17 million patients) at end-November 2025, down from 7.40 million treatments (6.24 million patients) in October and the lowest level since February 2023. Long-wait figures also improved: an estimated 1,500 patients had waited more than 18 months (down from 1,716 in October and 2,054 a year earlier), and 9,521 had waited more than 65 weeks (down from 12,542). The Health Secretary credited record investment and operational changes, while warning winter pressures persist—relevant for positioning around UK healthcare exposure and government service-delivery narratives.

Analysis

Market structure: A falling NHS waiting list tightens short-term demand for private-pay elective care but likely increases contracted work for independent-sector providers used by NHS surgical hubs. Winners: diagnostics chains, NHS-contracted private operators and healthcare IT vendors executing evening/weekend capacity; losers: self-pay-heavy private hospitals if NHS capacity absorption continues. The change (−90k treatments month-on-month, −312k year-to-date) implies a material reallocation of ~4–6% of marginal elective volumes back to NHS channels over 3–12 months.

Risk assessment: Tail risks include a severe winter COVID/respiratory spike or a budgetary reversal after elections that could re-expand waiting lists by >5% in 1–3 months, and contracting/accounting changes that temporarily inflate treated volumes. Immediate risk (days–weeks): data revisions and monthly volatility; short-term (1–3 months): contract award cadence and winter pressures; long-term (>6 months): structural funding and capacity investment. Hidden dependency: independent sector revenue depends on NHS contracting cadence, not just patient flow.

Trade implications: Direct trades favor stocks with high NHS-contracted revenue and diagnostics exposure; relative shorts on self-pay–dependent names. Use 3–6 month pair trades and tight option-defined risk (buy-call spreads) around contract-award windows. Cross-asset: slight positive GBP bias and marginal easing of short-term gilt risk premia if health-service pressures stay lower.

Contrarian: Consensus treats improved lists as uniformly negative for private hospitals; the nuance is that NHS outsourcing can raise independent-sector revenues and margins. If NHS continues to buy capacity (surgical hubs), independent operators with contract execution capability (not self-pay mix) can outperform by 10–25% over 6–12 months. Watch for procurement delays which would flip the trade quickly.

Key Decisions for Investors

• Establish a 2–3% long position in Circle Health Group (LSE:CIRC) over the next 4–8 weeks to capture NHS independent-sector contract flow; target +15% upside in 6–12 months, stop-loss −8% (unwind if monthly NHS treated volumes decline >3%).
• Initiate a 2% short or underweight position in Spire Healthcare (LSE:SPI) versus benchmark over 1–3 months due to higher self-pay exposure; cover if SPI trades 20% below entry or if company confirms >30% NHS revenue share in next quarter.
• Deploy a 1% capital buy-call spread on CIRC.L (6-month expiry, buy near-the-money, sell 10–15% OTM) to express directional upside with defined risk around upcoming contract-award windows.
• Overweight UK-listed diagnostics/health IT contractors (allocate +2% vs benchmark) and underweight pure private-pay elective operators (−2%); rebalance if NHS waiting list increases >1% month-on-month or winter admissions exceed historical average by >10%.